Evommune's EVO756 Misses Endpoints in Atopic Dermatitis, Second Phase 2b Setback in Two Months
- EVO756, Evommune's oral MRGPRX2 antagonist, missed the primary and secondary endpoints of a Phase 2b trial in 121 adults with moderate-to-severe atopic dermatitis.
- The primary endpoint — percent change in EASI score at Week 12 — was not met at any dose; the drug was described as generally well tolerated.
- Evommune will not advance EVO756 further in atopic dermatitis, its second Phase 2b failure in about two months after an earlier miss in chronic spontaneous urticaria.
- The company's lead AD program now shifts to EVO301, an IL-18BP fusion protein with positive Phase 2a data; a Phase 2b trial is planned for mid-2027.
- EVO756 development continues separately in migraine prophylaxis, where a Phase 2b study has begun dosing patients.
Two Phase 2b misses in two months turns a mechanism question into a mechanism problem: MRGPRX2 antagonism was Evommune's platform bet across AD, CSU and migraine, and when the same target fails to move the needle in two distinct inflammatory indications, the more parsimonious read isn't "wrong molecule" — it's "wrong biology." The tell is the pivot itself: rather than pushing EVO756 into a third dermatology indication, Evommune is handing the lead AD slot to EVO301, an entirely different IL-18BP mechanism, while EVO756 gets demoted to a migraine hedge nobody's betting the company on. That leaves Evommune effectively a single-shot story riding on EVO301's 2027 Phase 2b — a long runway to prove out with a thinner cushion, and exactly the kind of back-to-back-failure narrative that compresses valuation and stiffens terms on whatever financing round comes next.
Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer ↗